Investigation of possible associations between tryptophan/kynurenine status and FOXP3 expression in colorectal cancer

References

• Terry P, Giovannucci E, Michels KB, et al. Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst. 2001;93(7):525–533.
   PubMedGoogle Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J. Gen. Physiol. 1927;8(6):519–530.
   PubMedGoogle Scholar
• Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95.
   PubMed Web of Science ®Google Scholar
• Löb S, Königsrainer A, Rammensee H-G, et al. Inhibitors of indoleamine-2,3- dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer. 2009;9(6):445–452.
   PubMed Web of Science ®Google Scholar
• Platten M, Knebel Doeberitz N, Oezen I, et al. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol. 2014;5:673.
   PubMed Web of Science ®Google Scholar
• Peters JC. Tryptophan nutrition and metabolism: an overview. Adv Exp Med Biol. 1991;294:345–358.
   PubMedGoogle Scholar
• Austin CJD, Rendina LM. Targeting key dioxygenases in tryptophan-kynurenine metabolism for immunomodulation and cancer chemotherapy. Drug Discov Today. 2015;20(5):609–617.
   PubMed Web of Science ®Google Scholar
• Santhanam S, Alvarado DM, Ciorba MA. Therapeutic targeting of inflammation and tryptophan metabolism in colon and gastrointestinal cancer. Transl. Res. 2016;167(1):67–79.
   PubMed Web of Science ®Google Scholar
• Grimmig T, Kim M, Germer CT, et al. The role of FOXP3 in disease progression in colorectal cancer patients. Oncoimmunology. 2013;2(6):e24521–e24523.
   PubMed Web of Science ®Google Scholar
• Uva V, Sfondrini L, Triulzi T, et al. FOXP3 expression in tumor cells and its role in cancer progression. Atlas Genet. Cytogenet. Oncol. Haematol. 2015;19:234–239.
   Google Scholar
• Löb S, Königsrainer A, Zieker D, et al. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother. 2009;58(1):153–157.
   PubMed Web of Science ®Google Scholar
• Bellanti JAI. IV: Clinical applications in health and disease; 2019. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651157.
   Google Scholar
• Nugent JL, McCoy AN, Addamo CJ, et al. Altered tissue metabolites correlate with microbial dysbiosis in colorectal adenomas. J Proteome Res. 2014;13(4):1921–1929.
   PubMed Web of Science ®Google Scholar
• Chou C, Pinto AK, Curtis JD, et al. c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells. Nat Immunol. 2014;15(9):884–893.
   PubMed Web of Science ®Google Scholar
• Llosa NJ, Cruise M, Tam A, et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2015;5(1):43–51.
   PubMed Web of Science ®Google Scholar
• Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21(8):938–945.
   PubMed Web of Science ®Google Scholar
• Giannakis M, Mu XJ, Shukla SA, et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 2016;15(4):857–865.
   PubMed Web of Science ®Google Scholar
• Caro D, Marchesi G, Laghi F, et al. F. Immune cells: plastic players along colorectal cancer progression. J Cell Mol Med. 2013;17(9):1088–1095.
   PubMed Web of Science ®Google Scholar
• De la Cruz-Merino L, Henao Carrasco F, Vicente Baz D, et al. Immune microenvironment in colorectal cancer: a new hallmark to change old paradigms. Clin Dev Immunol. 2011;2011:174149.
   PubMedGoogle Scholar
• Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013;19(11):1423–1437.
   PubMed Web of Science ®Google Scholar
• Khong HT, Restifo NP. Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat Immunol. 2002;3(11):999–1005.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372(15):1441–1452.
   PubMed Web of Science ®Google Scholar
• Arthur JC, Gharaibeh RZ, Mühlbauer M, et al. Microbial genomic analysis reveals the essential role of inflammation in bacteria-induced colorectal cancer. Nat. Commun. 2014;5:4724.
   PubMed Web of Science ®Google Scholar
• Kim M, Grimmig T, Grimm M, et al. Expression of Foxp3 in colorectal cancer but not in treg cells correlates with disease progression in patients with colorectal cancer. PLOS One. 2013;8(1):e53630.
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos F, Papadaki H, Antonacopoulou AG, et al. Association of FOXP3 expression with non-small cell lung cancer. Anticancer Res. 2011;31(5):1677–1683.
   PubMed Web of Science ®Google Scholar
• Fu H, Li C, Yang W, et al. FOXP3 and TLR4 protein expression are correlated in non-small cell lung cancer: implications for tumor progression and escape. Acta Histochem. 2013;115(2):151–157.
   PubMed Web of Science ®Google Scholar
• Winerdal ME, Marits P, Winerdal M, et al. FOXP3 and survival in urinary bladder cancer. BJU Int. 2011;108(10):1672–1678.
   PubMed Web of Science ®Google Scholar
• Yoshii M, Tanaka H, Ohira M, et al. Expression of forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the ll carcinoma of the stomach. Br J Cancer. 2012;106(10):1668–1674.
   PubMed Web of Science ®Google Scholar
• Chatrabnous N, Ghaderi A, Ariafar A, et al. Serum concentration of interleukin-35 and its association with tumor stages and FOXP3 gene polymorphism in patients with prostate cancer. Cytokine. 2019;113:221–227.
   PubMed Web of Science ®Google Scholar
• Chen L, Yu Q, Liu B, et al. Association of FoxP3 rs3761548 polymorphism with susceptibility to colorectal cancer in the Chinese population. Med. Oncol. 2014;31:1–4.
   Web of Science ®Google Scholar
• Jiang W, Zheng L, Xu L, et al. Association between FOXP3, FOXE1 gene polymorphisms and risk of differentiated thyroid cancer in Chinese Han population. Mol Biol. 2015;4:3.
   Google Scholar
• Haghighi MF, Ghayumi MA, Behzadnia F, et al. Investigation of FOX. P3 Genetic variations at positions -2383 C/T and IVS9 + 459 T/C in Southern Iranian patients with lung carcinoma. Iran J Basic Med Sci. 2015;18(5):465–471.
   PubMed Web of Science ®Google Scholar
• You D, Wang Y, Zhang Y, et al. Association of Foxp3 promoter polymorphisms with susceptibility to endometrial cancer in the Chinese Han women. Medicine. 2018;97(18):e0582.
   PubMed Web of Science ®Google Scholar
• Zheng J, Deng J, Jiang L, et al. Heterozygous genetic variations of FOXP3 in Xp11.23 elevate breast cancer risk in Chinese population via skewed X-chromosome inactivation. Hum Mutat. 2013;34(4):619–628.
   PubMed Web of Science ®Google Scholar
• Jiang LL, Ruan LW. Association between FOXP3 promoter polymorphisms and cancer risk: a meta-analysis. Oncol Lett. 2014;8(6):2795–2799.
   PubMed Web of Science ®Google Scholar
• Engin AB, Karahalil B, Karakaya AE, et al. Helicobacter pylori and serum kynurenine- tryptophan ratio in patients with colorectal cancer. WJG. 2015;21(12):3636–3643.
   PubMed Web of Science ®Google Scholar
• Liu X, Shin N, Koblish HK, et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood. 2010;115(17):3520–3530.
   PubMed Web of Science ®Google Scholar
• Ferdinande L, Decaestecker C, Verset L, et al. Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J Cancer. 2012;106(1):141–147.
   PubMed Web of Science ®Google Scholar
• De Jong RA, Nijman HW, Boezen HM, et al. Serum tryptophan and kynurenine concentrations as parameters for indoleamine 2,3-dioxygenase activity in patients with endometrial, ovarian, and vulvar cancer. Int. J. Gynecol. Cancer. 2011;21:1320–1327.
   PubMed Web of Science ®Google Scholar
• Schroecksnadel K, Winkler C, Fuith LC, et al. Tryptophan degradation in patients with gynecological cancer correlates with immune activation. Cancer Lett. 2005;223(2):323–329.
   PubMed Web of Science ®Google Scholar